ChiCTR2000030055.

Study name	Multicentre study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID‐19)
Methods	Trial design: prognosis, parallel multicentre trial Type of publication: trial registration Recruitment dates: February 2020 to March 2020 Country: China Language: English Number of centres: multicentre (6 centres) Inclusion criteria: suspected cases of neo‐coronary pneumonia (outside Hubei province), clinically diagnosed cases (in Hubei province), and light/general confirmed cases, severe/critical confirmed cases, aged 18 to 70 years Exclusion criteria: patients with presence, coagulopathy or hypotension; pregnant and lactating women; people with allergies or allergies to Xuebijing Injection and its components; severe basic diseases that affect survival, including: uncontrolled malignant tumours that have metastasised and cannot be removed, blood diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.; pulmonary tumours caused by obstructive pneumonia, severe interstitial fibrosis, alveolar proteinosis, allergic alveolitis; continued use of immunosuppressive agents or organ transplants in the last 6 months; extracorporeal life support (ECMO, ECCO2R, RRT); expected deaths within 48 hours; clinicians judge inappropriate. Trial registration number: ChiTR2000030055 Date of trial registration: February 2020 Prospective completion date: NR
Participants	Age: 18 to 70 years Gender: female/male Ethnicity: NR Number of participants (recruited/allocated/evaluated): 460 planned Severity of disease: severe disease (diagnosis of severe case was made if patients met any of the following criteria: (1) respiratory failure which requiring mechanical ventilation; (2) shock; (3) combined with other organ failure, need to be admitted to ICU) Additional diagnosis: NR
Interventions	Drug: dipyridamole 150 mg via orally 3 times a day for 7 days Concomitant therapy: all patients received antiviral (ribavirin, 0.5 g, every 12 hours), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, and nutritional support as necessary Treatment cross‐overs: NR Duration of follow‐up: NR Compliance with assigned treatment: NR
Outcomes	Primary outcomes: complete blood count, CRP, blood coagulation, D‐dimer, virological examination of pharyngeal swab, pulmonary imaging Secondary outcomes: NR Additional outcomes: NR
Starting date	March 2020
Contact information	Qingling Zhang Tel.: +86 13609068871 E‐mail: zqling68@hotmail.com Address: 151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China
Notes	Funding: National Key R&D Program of China, National Natural Science Foundation of China, Taikang Insurance Group Co., Ltd and Beijing Taikang Yicai Foundation and philanthropy donation from individuals.